Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-185: Pembrolizumab in Newly Diagnosed Multiple Myeloma
NCT02579863Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Primary completion
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in multiple myeloma (MM), sponsored by Merck & Co.. Started Oct 2015; status: terminated.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02579863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579863.